CSBIO(SZ:300255) Xin Lang Cai Jing·2025-10-16 01:32Core Viewpoint - Changshan Pharmaceutical experienced a 3.44% increase in stock price on October 15, with a trading volume of 1.451 billion yuan, indicating strong market interest and activity [1]. Financing Summary - On October 15, Changshan Pharmaceutical had a financing buy-in amount of 208 million yuan, with a net financing buy of 94.32 million yuan after 114 million yuan in financing repayments [1]. - The total financing and securities lending balance reached 2.093 billion yuan, accounting for 4.54% of the circulating market value, which is above the 90th percentile of the past year, indicating a high level of financing activity [1]. - The securities lending data showed no shares were sold or repaid on October 15, with a remaining balance of 5020 yuan, which is above the 70th percentile of the past year, suggesting a relatively high level of securities lending [1]. Company Performance - As of October 10, the number of shareholders for Changshan Pharmaceutical was 45,700, a decrease of 2.04% from the previous period, while the average circulating shares per person increased by 2.08% to 20,094 shares [2]. - For the first half of 2025, the company reported a revenue of 492 million yuan, a year-on-year decrease of 13.42%, and a net profit attributable to shareholders of -29.09 million yuan, reflecting a 37.98% increase compared to the previous year [2]. Dividend and Shareholding Information - Since its A-share listing, Changshan Pharmaceutical has distributed a total of 181 million yuan in dividends, with 4.5953 million yuan distributed over the last three years [3]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 10.5521 million shares, an increase of 8.0391 million shares from the previous period [3].